perform per expect
downgrad rate hold abbott maintain
tp provid upsid potenti
deriv estim base forward price-to-earnings
multipl ep estim top-lin
revenu grow
optimist perform per
expect recommend hold rate upsid potenti
less rise
estim base follow factor strong growth
across segment robust portfolio product new product
launch quarter
abbott deliv strong result due strong growth across
segment total revenu increas
sale grew organ basi adjust ep
ep
diagnost segment grew due strong pace
alin launch europ quarter rapid diagnost
busi growth driven infecti diseas cardiometabol
establish pharmaceut busi grew due
growth india china nutrit busi grew
due strong perform intern busi
medic devic busi grew due double-digit growth
electrophysiolog structur heart diabet busi
quarter
abbott declar quarterli dividend per share june
increas dividend pay-out consecut year
compani nametickerabtstock ratingholddowngradeindustri viewoverweightpositivepric aug week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth august
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
may abbott receiv approv fda xienc
sierra also receiv nation reimburs japan
treat peopl coronari arteri diseas may abbott
announc fda clearanc advisor hd grid map
approv next-gener version lead mitraclip
ytd stock perform higher
 roa roi roe ttm ttm
perform
abbott expect ep expect adjust
ep organ sale growth
expect expect adjust gross
margin ratio sale adjust sale
adjust sg expens sale
current price-to-earnings trade
price-to-earnings went averag price-to-earnings
price-to-earnings show upward trend due
increas stock price expect forward price-to-earnings multipl
recommend hold rate stock stock price
increas quarter upsid potenti
estim also base
abbott perform strong portfolio
product per expect
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date aug ex-dividend date jul last split factor new per last split date jan inform abbott laboratori august
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper oper profit interest incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli august
 market account receivable- total prepaid current total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr liabilities- minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbott laboratori august
net cash oper activ compar prior-year period
increas due higher segment oper earn continu improv work capit
manag time pension contribut lower acquisition-rel expens
net cash use invest activ compar prior-year period net cash
use financ activ compar prior period
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end august
abbott deliv strong result due strong growth across segment
deliv double-digit revenu earn growth quarter
increas
compar
due strong
growth across
total revenu increas compar
organ sale increas organ sale growth
exclud prior year result abbott medic optic amo st jude
medic vascular closur busi divest
exclud current prior year result rapid diagnost reflect
result aler inc acquir oct
exclud impact foreign exchang
compar
gross margin ratio
sale
total revenu increas compar
total intern revenu increas
compar
sale diagnost acquir late last year
includ organ sale growth result exchang
favor y/i impact sale quarter
dollar strengthen vs sever currenc result less favor impact
sale
cog increas compar
amort intang asset increas
compar gross margin increas
compar adjust gross margin ratio sale
gross margin increas due favor comparison vs prior
year includ inventori step-up amort relat st jude medic
acquisit increas also due margin improv variou
busi includ diabet cardiovascular neuromodul
 expens increas compar
adjust invest sale increas
due addit acquir aler busi well higher spend
area cardiovascular neuromodul
sg expens increas compar
adjust sg expens sale increas
due addit acquir aler busi well higher spend
drive continu growth market expans variou busi partial
off-set lower acquisition-rel expens
total oper expens increas compar
oper incom increas compar
interest expens increas compar
effect tax rate compar
net incom increas compar
adjust net incom increas compar
gaap ep increas compar non-gaap
ep increas compar
gaap ep increas
compar
non-
gaap ep increas
compar
compar
total revenu increas compar
total revenu increas
compar total intern revenu increas
compar increas revenu
due strong growth across busi segment
cog increas compar
amort intang asset increas
compar gross margin compar
increas due favor comparison vs prior
year includ inventori step-up amort relat st jude medic
acquisit increas also due margin improv variou
busi includ diabet cardiovascular neuromodul
 expens increas compar
 expens cardiovascular
neuromodul product segment diagnost product
segment nutrit product segment
compar
sg expens increas compar
increas due addit acquir aler busi
well higher spend drive continu growth market expans variou
busi partial off-set lower acquisition-rel expens
oper expens increas compar
oper incom compar
interest expens flat compar prior-year period
effect tax rate declin compar
tax expens earn continu oper includ impact
excess tax benefit associ share-bas compens
net incom increas compar
adjust net incom increas
compar
gaap ep increas compar
non-gaap ep increas compar
gaap ep increas
compar
increas
compar
abbott oper differ segment establish pharmaceut
product nutrit diagnost medic devic total revenu
segment increas compar
total revenu increas
compar segment revenu total revenu
follow
total revenu
segment increas
compar
increas
report basi
compar
establish pharmaceut sale increas report
basi compar includ
unfavor effect foreign exchang total revenu increas
compar
key emerg market compris sever countri repres
attract long-term growth opportun abbott brand
sale geographi increas report basi
includ unfavor effect foreign exchang
revenu increas organ basi sale growth due
double-digit growth across sever geographi includ india china
world-wide revenu nutrit segment increas
report basi compar
sale includ favor effect foreign exchang increas
organ basi
total revenu increas compar
previou year quarter total revenu increas
total intern revenu increas
compar previou year quarter total intern revenu
increas
world-wide pediatr nutrit revenu increas
compar previou year quarter includ favor effect
foreign exchang increas organ basi total revenu
increas compar prior-year period
total revenu increas compar
previou year quarter total revenu increas
compar prior-year period
total intern revenu increas report basi
compar previou year quarter includ
favor effect foreign exchang increas organ
basi total revenu increas compar
prior-year period
world-wide revenu
increas
report basi
compar
increas
compar previou
year quarter
strong perform quarter led growth sever countri
across asia includ greater china latin america
total revenu increas compar
previou year quarter includ favor effect foreign
exchang increas organ basi total revenu
increas compar prior-year period
total revenu rel flat compar
previou year quarter total revenu increas
compar prior-year period
total intern revenu increas report basi
compar previou year quarter includ
favor effect foreign exchang increas organ
basi total revenu increas compar
prior-year period
sale perform led strong growth ensur abbott market-
lead complet balanc nutrit brand glucerna abbott
world-wide diagnost revenu increas
compar revenu increas
organ basi total revenu increas
compar
compar
previou year
revenu increas
compar
diagnost product revenu increas
compar previou year quarter total revenu
increas compar prior-year period
diagnost product intern revenu increas
compar previou year quarter total intern
revenu increas compar prior-
laboratori diagnost revenu increas
compar previou year quarter includ favor
effect foreign exchang increas organ basi
total revenu increas compar
growth laboratori diagnost revenu quarter
driven continu share gain global total intern revenu
increas compar previou year
quarter total revenu increas
compar previou year quarter
diagnost revenu led infecti
diseas cardiometabol test rapid diagnost reflect sale
aler inc acquir oct total revenu
rapid diagnost revenu
total intern revenu
molecular diagnost revenu increas report basi
compar previou year quarter includ
favor effect foreign exchang increas organ
basi total revenu increas compar
revenu
increas
compar previou
year quarter
revenu
led
infecti diseas
world-wide molecular diagnost revenu led strong growth
infecti diseas test partial off-set plan scale
test area primarili total revenu declin
compar previou year quarter total
intern revenu increas compar
previou year quarter
point diagnost revenu rel flat
compar previou year quarter includ favor
effect foreign exchang decreas organ basi total
revenu increas compar
total revenu declin total
intern revenu increas
world-wide medic devic sale increas report basi
compar previou year quarter organ
basi sale increas total revenu increas
compar prior-year period
medic devic revenu increas
compar previou year quarter total intern revenu
increas compar previou year
cardiovascular neuromodul revenu increas
compar previou year quarter revenu
increas compar prior-year period
total revenu increas compar
previou year quarter sale growth led double-digit
growth electrophysiolog structur heart
cardiovascular
revenu increas
compar
previou year
quarter due double-
digit growth
electrophysiolog
electrophysiolog revenu increas
compar previou year quarter total revenu increas
compar prior-year period total revenu
 increas compar previou year
quarter total intern revenu increas
compar previou year quarter
electrophysiolog growth led strong perform cardiac
map ablat growth also due share gain
recent launch abbott confirm rxtm insert cardiac monitor
icm world first smartphone-compat icm design
structur heart revenu increas
compar previou year quarter total revenu increas
compar prior-year period total revenu
 increas compar previou
year period total intern revenu increas
compar previou year quarter
growth structur heart due sever product area across
abbott broad portfolio includ amplatzertm pfo occlud
mitraclip abbott market-lead devic minim invas
treatment mitral regurgit
diabet revenu increas
compar previou year quarter total revenu increas
compar prior-year period total revenu
 increas compar previou
year quarter total intern revenu increas
compar previou year quarter
diabet revenu increas organ basi
growth led continu rapid market uptak freestyl
growth led strong
perform cardiac
map ablat
revenu increas
compar
previou year
may abbott announc fda clearanc advisor hd grid map
cathet sensor enabl creat highli detail map heart
abbott receiv approv fda xienc sierra
newest gener gold-standard coronari stent system
offer design technolog advanc provid easier implant
greater abil treat complex blockag quarter xienc sierra
also receiv nation reimburs japan treat peopl coronari
juli abbott announc fda approv next-gener version
mitraclip enhanc design provid even greater precis
test system diabet manag
abbott launch ensur max protein help refuel bodi
gram high-qual protein sugar
abbott expand real-world evid freestyl libr user
show higher frequenc scan associ improv glucos
guidanc conclus
abbott project adjust ep
ep
abbott expect organ sale growth rang
expect adjust gross margin ratio sale adjust
od sale adjust sg expens sale
abbott forecast net specifi item per share
expens charg associ cost reduct initi
expect ep non-gaap ep
would
abbott forecast specifi item primarili relat
initi expens
abbott deliv strong result due strong product pipelin strateg
step taken abbott posit attract area healthcar
revenu increas due strong growth across
segment ep adjust ep
may abbott receiv approv fda xienc sierra also
receiv nation reimburs japan treat peopl coronari arteri
diseas may abbott announc fda clearanc advisor hd grid
map cathet sensor enabl juli abbott receiv fda approv
next-gener version lead mitraclip heart valv repair devic
ytd stock perform higher roa
roi roe ttm ttm ttm respect abbott
expect continu strong perform
adjust ep
ep
result due strong
product pipelin
strateg step taken
abbott posit
attract
area healthcar
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin increas ttm compar due decreas cog
oper margin declin ttm compar
y/i revenu growth ttm compar
y/i ep growth ttm compar
net margin increas ttm compar due declin tax rate
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott laboratori august
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale abbott laboratori august
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn asset abbott laboratori august
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott laboratori august
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free august
current price-to-earnings trade price-to-earnings increas
averag price-to-earnings price-to-earnings show
upward trend due increas stock price expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form daniel mile michael stephen eric thoma richard john robert brian institut holdersholdershar report outvaluevanguard group inc capit research global wellington manag compani massachusett servic northern trust price row associ well fargo top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard growth fund america spdr etf vanguard specialized-health vanguard institut fund-institut invest compani vanguard specialized-dividend appreci amcap mf seri trust i-mf valu august
developmentsabbott expand direct deep brain stimul therapi offer new mr-condit labelingabbott announc fda approv over-the-air softwar upgrad current implant infin db system deliv magnet reson mr -condit label innov featur thislife-chang technolog abbotthelp patient progress diseas live better abbott freestyl libr day flash glucos monitor approv abbott announc food drug administr fda approv freestylelibr day flash glucos monitor system allow peopl diabet wear sensor day high accuraci approv make abbott revolutionari continu glucos monitor cgm longest last self-appli person glucos sensor avail market abbott receiv fda approv next-gener mitraclip devic treat peopl leaki heart valvesabbott announc receiv approv food drug administr fda next-gener version lead mitraclipheart valv repair devic use repair leaki mitral valv without open-heart surgeri transcathet clip-bas therapi third gener product innov use treat patient world-wide last ten year abbott introduc afinion analyz test diabet managementabbott announc launch afinion analyz newest gener afinion test system afinion build abbott heritag diabet care empow patient inform health discuss provid singl visit juli abbott laboratori august
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott laboratori august
consensu view analyst trend stock
forecast vs
abbott forward price-to-earnings
vs
abt avgfive-year growth forecast usdgrowth high day day day estim comparisonabtindustri avg avgprice/earn yield august
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
current qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr abbott laboratori august
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price show huge fluctuat quarter gave return
stock price show upward trend averag trade volum
stock price movement show upward trend last one year current trade
stock gave return last one year rang stock
stock price movement shown upward trend sinc gave return past
stock volatil increas volum share trade
abbott deliv strong perform due continu growth across segment
recommend hold rate abbott maintain tp deriv tp
forward look price-to-earnings ep
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
